Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
@article{Bresalier2005CardiovascularEA, title={Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.}, author={Robert S. Bresalier and Robert S. Sandler and Hui Quan and James A. Bolognese and Bettina Oxenius and Kevin J. Horgan and Christopher R. Lines and Robert H Riddell and Dion G. Morton and {\'A}ngel Lanas and Marvin A. Konstam and John A. Baron}, journal={The New England journal of medicine}, year={2005}, volume={352 11}, pages={ 1092-102 } }
BACKGROUND
Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of…
2,531 Citations
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
- MedicineThe Lancet
- 2008
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
- MedicineThe New England journal of medicine
- 2005
Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure, providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
- MedicineThe New England journal of medicine
- 2007
Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration, and died from cardiovascular causes during the follow-up period.
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
- MedicineGastroenterology
- 2007
Among patients with a history of colorectal adenomas, the long-term use of 25 mg/day of rofecoxib was associated with an increased risk of clinically relevant upper gastrointestinal events when compared with placebo.
COX 2 inhibitors, traditional NSAIDs, and the heart
- MedicineBMJ : British Medical Journal
- 2005
Rofecoxib had been marketed as the non-steroidal anti-inflammatory drug (NSAID) of choice because selective inhibition of the isoform 2 of the cyclooxygenase (COX 2) enzyme made it highly effective but free from gastrointestinal toxicity.
Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies
- MedicineExpert opinion on drug safety
- 2014
Results are ambiguous: long-term exposure seemed associated with an increased risk of myocardial infarction or stroke with high-dose rofecoxib, and perhaps diclofenac, but less with other NSAIDs, since most NSAIDs are rarely used long term.
Relative Thromboembolic Risks Associated with COX-2 Inhibitors
- MedicineThe Annals of pharmacotherapy
- 2005
OBJECTIVE To evaluate the clinical literature on cyclooxygenase-2 (COX-2) inhibitors to determine whether a greater incidence of thromboembolic events is universal within the drug class. DATA SOURCES…
Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas
- MedicineCirculation
- 2006
Background— Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk. Methods and Results— The Adenoma Prevention…
Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis
- MedicineCancer management and research
- 2019
Celecoxib 400 mg once daily dosing could potentially be considered as a viable chemopreventive option in patients with high risk of adenomas but with low CV risk, and analysis of post-trial studies indicated that the treatment effect disappeared.
Celecoxib for the prevention of colorectal adenomatous polyps.
- MedicineThe New England journal of medicine
- 2006
The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy.
References
SHOWING 1-10 OF 33 REFERENCES
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
- MedicineThe New England journal of medicine
- 2005
Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure, providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
- MedicineAnnals of Internal Medicine
- 2005
A casecontrol study from 36 hospitals in a 5-county area found that reported recent use of a COX-2 selective inhibitor was similar among adults with a first, nonfatal myocardial infarction (MI) and randomly selected community controls with no history of MI, however, reported use of rofecoxib was associated with a higher odds of MI than was use of celecoxib.
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
- MedicineThe American journal of cardiology
- 2002
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
- MedicineCirculation
- 2004
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
- MedicineAmerican journal of therapeutics
- 2001
Patients taking antihypertensive therapy and receiving cyclooxygenase-2–specific inhibitors should be monitored for the development of cardiorenal events.
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
- Medicine
- 2000
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
- MedicineArchives of internal medicine
- 2003
The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice and do not support a short- term reduced risk ofAMI with naproxen.
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
- MedicineAmerican heart journal
- 2003
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
- Medicine
- 2003
It is confirmed that aspirin lowers the risk of recurrent colorectal adenoma in those having one or more adenomas recently removed, and the protective effect is of a moderate degree.